## Embracing Heterogeneity in Evidence Synthesis to Inform Intervention Development

**Brian Williams** 



### Reduction in risk of heart disease by strategies for lowering cholesterol.



Greenhalgh T BMJ 1997;315:672-675

## Some Practical Questions

- Does it work?
- What is "it"?
- What do I need to replicate it here? (how does it work? What will it cost etc)
- If I replicate it here will I get the same results?

### Reduction in risk of heart disease by strategies for lowering cholesterol.



Greenhalgh T BMJ 1997;315:672-675

## Working after cancer: a systematic review, metaregression and explanatory metasynthesis of the qualitative evidence

Dr Mary Wells, Brian Williams, Thilo Kroll





### Cancer Survivors and Unemployment A Meta-analysis and Meta-regression

COMP An Origen Million Americanism. All rights read-real.

 Angela L. E. M. do Born, PhD
 Context Numbry half of adult concersaries any parager Bars 62 years, but the su-colution of concersaries and biggines. The subscription of table is unknown.

 Assell Diggines, PhD
 Objective To concers and exclusion of concersaries and biggines.

 Frank J. H. van Diggines, PhD
 Objective To concers and exclusion of concersaries and biggines.

 Frank J. H. van Diggines, PhD.
 Objective To concers and exclusion of concersaries and biggines.

 Frank J. H. van Diggines, PhD.
 Objective To concersaries and biggines.

 Dark J. M. Variesed, PhD.
 Objective To concersaries and biggines.

 Dark J. M. Variesed, PhD.
 Objective To concersaries and biggines.

 Dark J. M. Variesed, PhD.
 Objective To concersaries and biggines.

 Dark J. M. Variesed, PhD.
 Objective To concersaries and biggines.

 Dark J. M. Variesed, PhD.
 Objective To concersaries and biggines.

 Dark L. A. Variesed, PhD.
 Objective To concersaries and biggines.

 Dark L. A. Variesed, PhD.
 Objective To concersaries and biggines.

 Dark L. A. Variesed, PhD.
 Objective To concersaries and biggines.

CLINICIAN'S CORNER

<text><text><text><text><text><text><text><text><text><text><text><text><text>

(Reprinted) 346A, February 18, 2006 ... Vol. 201, No. 7 1783

Table 4. Results of Univariate and Multivariate Bayesian Meta-regression Models With Crude and Adjusted Meta-relative Risks for Prognostic Factors

		All Studies (n = 36)			High-Quality Studies <sup>a</sup>	
Factor	No. of Studies	Crude Meta-RR (95% Crl) Univariate	Adjusted Meta-RR (95% Crl) Multivariate <sup>b</sup>	No.	Adjusted Meta-RR (95% Crl) Multivariate (n = 25) <sup>b</sup>	
Country Europe	16	1 [Reference]	1 [Reference]	15	1 [Reference]	
United States	15	1.48 (1.15-1.95)	1.24 (0.85-1.83)	7	0.98 (0.66-1.56)	
Other	5	1.47 (1.03-2.12)	1.16 (0.68-1.96)	3	1.34 (0.85-2.27)	
Cancer diagnosis Testicular	3	1 [Reference]	1 [Reference]	3	1 [Reference]	
Breast	10	1.35 (0.76-2.37)	1.20 (0.65-2.22)	6	1.15 (0.67-1.85)	
Prostate	3	1.21 (0.62-2.39)	1.17 (0.55-2.47)	3	1.28 (0.67-2.31)	
Blood	7	1.42 (0.77-2.64)	1.38 (0.79-2.50)	6	1.27 (0.74-2.04)	
Other or mixed	13	1.58 (0.90-2.75)	1.48 (0.87-2.56)	7	1.35 (0.84-2.09)	
Patient age 18-50 y	23	1 [Reference]	1 [Reference]	15	1 [Reference]	
>50 y	8	0.99 (0.70-1.40)	1.08 (0.70-1.69)	6	1.03 (0.72-1.46)	
Not reported	5	1.19 (0.81-1.77)	1.10 (0.70-1.77)	4	1.09 (0.69-1.65)	
Background unemployment rate	36	0.24 (0.11-0.54)	0.38 (0.11-1.27)	25	0.63 (0.21-1.99)	

Abbreviations: Crl, credibility interval; RR, relative risk.

<sup>a</sup>High quality denotes 16 points or greater on the MINORS test.

<sup>b</sup>Adjusted for all the other variables in the model.

 
 Angela C. E. M. do Boer, PhD
 Contrast
 Name hash for adult cancer survivon are younger than 65 years, but the su-sociation of cancer survivonship with employment stakes is unknown.
 action of carbor with employment itaus is unservers.
 Annell Opgins, PAD
 objective To assume the association of carbor and with the unserverse.
 Annell Opgins, PAD
 Dig. PAD
 Dig. PAD
 Dig. PAD
 Dig. Source A systematic under of statis published before 700
 Dig. Source A systematic under of statis published before 700

Trans J. R. Van Urgle, FRD, MD
 Data Sources: A systematic warch of studies published between 1%6 and June 2008
 was candeded using/MIDUINE, CINALE, SWBASE, PsycNEO, and OSH-ROM databases.

CLINICIAN'S CORNE

<text><text><text><text><text><text><text><text><text>

Many cancer survivors water and acc able to return to work after diagnosis and trachment.<sup>1</sup> Patients often regard re-turning to work as indicative of con-nients may pleie recovery<sup>6</sup> and regained nor-maky.<sup>6</sup> Employment is also associated ment of ca

CLINICAL REVIEW

00009 American Milital Americation. All rights realwr

Table 4. Results of Univariate and Multivariate Bayesian Meta-regression Models With Crude and Adjusted Meta-relative Risks for Prognostic Factors

Through a meta-synthesis of qualitative studies: High-Quality Studies\* with a higher quality of life.<sup>4</sup> The en-CME available online at ial limit www.jamaarchivescme.com and questions on p 784.

<sup>10</sup> Tatyle Castro G (1) Michaevill, HG Candiding Mile Ye resolution. Additional Information State and the prevailing unstate (Equivalence) (10 G in order Michaeville Michaeville Castrol Forman, 10 G in order Michaeville Michaeville (Equivalence) Michaeville (2004), No. 7 783			Crude Meta-RR	Adjusted		Adjusted Meta-RR (95%
Is there evid	en <u>ce to₀expla</u>	<b>in</b> it	<b>ne likely n</b>	nechanisn	ns b	Crl) Multivariate (n = 25) <sup>b</sup>
which these	variables im	pact	on return	to work?	15	1 [Reference]
	United States	15	1.48 (1.15-1.95)	1.24 (0.85-1.83)	7	0.98 (0.66-1.56)
	Other	5	1.47 (1.03-2.12)	1.16 (0.68-1.96)	3	1.34 (0.85-2.27)
Are there va	riables which	ı hav	e not bee	n include	d in	1 [Reference]
meta-regres	sion that mig	htim	redict?.37)	1.20 (0.65-2.22)	6	1.15 (0.67-1.85)
	Prostate	S	1.21 (0.62-2.39)	1.17 (0.55-2.47)	3	1.28 (0.67-2.31)
	Blood	7	1.42 (0.77-2.64)	1.38 (0.79-2.50)	6	1.27 (0.74-2.04)
	Other or mixed	13	1.58 (0.90-2.75)	1.48 (0.87-2.56)	7	1.35 (0.84-2.09)
	Patient age 18-50 y	23	1 [Reference]	1 [Reference]	15	1 [Reference]
	>50 y	8	0.99 (0.70-1.40)	1.08 (0.70-1.69)	6	1.03 (0.72-1.46)
	Not reported	5	1.19 (0.81-1.77)	1.10 (0.70-1.77)	4	1.09 (0.69-1.65)
	Background	36	0.24 (0.11-0.54)	0.38 (0.11-1.27)	25	0.63 (0.21-1.99)
	which these Are there va	which these variables im United States Other Are there variables which Meta-regression that mig Prostate Blood Other or mixed Patient age 18-50 y >50 y Not reported	which these       variables impact         United States       15         Other       5         Are there variables which have         meta-regression       that might prostate         Prostate       3         Blood       7         Other or mixed       13         Patient age       18-50 y       23         >50 y       8         Not reported       5	Is there evidence to explain the likely n which these variables impact on return United States 15 1.48 (1.15-1.95) Other 5 1.47 (1.03-2.12) Are there variables which have not bee meta-regression that might predict? 37) Prostate 1.21 (0.62-2.39) Blood 7 1.42 (0.77-2.64) Other or mixed 13 1.58 (0.90-2.75) Patient age 18-50 y 23 1 [Reference] >50 y 8 0.99 (0.70-1.40) Not reported 5 1.19 (0.81-1.77)	Is there evidence to explain the likely mechanism           which these variables impact on return to work?           United States         15         1.48 (1.15-1.95)         1.24 (0.85-1.83)           Other         5         1.47 (1.03-2.12)         1.16 (0.68-1.96)           Are there variables which have not been include         Interference         Interference           Interference         1.21 (0.62-2.39)         1.17 (0.55-2.47)           Blood         7         1.42 (0.77-2.64)         1.38 (0.79-2.50)           Other or mixed         13         1.58 (0.90-2.75)         1.48 (0.87-2.56)           Patient age         18-50 y         23         1 [Reference]         1 [Reference]           >50 y         8         0.99 (0.70-1.40)         1.08 (0.70-1.69)         Not reported         5         1.19 (0.81-1.77)         1.10 (0.70-1.77)	Is there evidence to explain the likely mechanisms b           which these         variables impact on return to work?         15           United States         15         1.48 (1.15-1.95)         1.24 (0.85-1.83)         7           Other         5         1.47 (1.03-2.12)         1.16 (0.68-1.96)         3           Are there variables         which have not been included in meta-regression         that might predict?         37         1.20 (0.65-2.22)         6           Prostate         5         1.21 (0.62-2.39)         1.17 (0.55-2.47)         3         3           Blood         7         1.42 (0.77-2.64)         1.38 (0.79-2.50)         6         6           Other or mixed         13         1.58 (0.90-2.75)         1.48 (0.87-2.56)         7           Patient age         18-50 y         23         1 [Reference]         1 [Reference]         15           >50 y         8         0.99 (0.70-1.40)         1.08 (0.70-1.69)         6           Not reported         5         1.19 (0.81-1.77)         1.10 (0.70-1.77)         4

unemployment rate

Abbreviations: Crl, credibility interval; RR, relative risk.

<sup>a</sup>High quality denotes 16 points or greater on the MINORS test.

<sup>b</sup>Adjusted for all the other variables in the model.

# Inclusion of papers

- 13,233 titles & abstracts screened for relevance
- 69 full papers obtained
- 48 excluded not qualitative, no relevant data
- 21 quality appraised
- 2 located via experts
- 2 located from journals 'in press'
- 19 'full' papers, 6 'partial'

### Papers by country



Papers by cancer site







### Intervention description is not enough: evidence from an in-depth multiple casestudy on the untold role and impact of context in RCTs of 7 Complex Interventions.

Mary Wells, Shaun Treweek, Julie Taylor, Brian Williams





	Number and nature of participants / documents	Total number of data sources (interviews, focus groups & documents)
	Phase 1: Single Exploratory Case	
Interviews	13 longitudinal interviews with 4 Breast care nurse: Three interviewed 3 times. One interviewed 4 times. Plus: One interview with a research nurse And one interview with a charge nurse	15
Documents	Protocol, Ethics application, Monitoring reports x 2, Final report, Minutes of meetings x 15, Field notes of PI and researcher	22
	Phase 2: Multiple Explanatory Case Study	
Interviews	7 Principal Investigators and 1 research assistant	8
Documents	7 trial protocols / proposals 6 ethics forms 5 monitoring reports 7 final reports 5 published papers	30
Focus groups	1 group with 3 Research nurses 1 group with 2 Nurse members of the Ethics committee 1 group with 4 PIs	9
Total		84

	Number and nature of participants / documents         Phase 1: Single Exploratory Case	Total number of data sources (interviews, focus groups & documents)
Interviews	13 longitudinal interviews with 4 Breast care nurse: Three interviewed 3 times.	15
• Documer	Personal, organisational, trial and problem conte are crucial to understanding how a complex intervention works	22
Interview Documer	The ways in which context challenged trial operatives often complex, idiosyncratic, and subtle; offer falling outside of current trial reporting formats.	
• Focus gro	Information on such issues appeared to be availated via first hand "insider accounts" of each trial suggesting that improved reporting on the role of context is possible.	
Total	1 group with 4 PIs	84

"We have a habit of writing articles published in scientific journals to make the work as finished as possible, to cover up all the tracks, to not worry about the blind alleys or describe how you had the wrong idea first, and so on. So there isn't any place to publish, in a dignified manner, what you actually did in order to get to do the work"

Richard Feynman 1965

A Meta-Regression and Multiple Case Study to Inform the Development of an Improved Ante and Postnatal Weight Management Intervention: Learned the Lessons from Existing RCTs.

Maggie Styles, Helen Cheyne, Jon Godwin, Annie Anderson, Brian Williams



Nursing, Midwifery and Allied Health Professions Research Unit

## Some concluding thoughts:

- Heterogeneity can be helpful
- Analysis of past RCTs may help to identify parameters that predict success i.e. mechanisms that define the intervention.
- But......we need more honest and open reporting of trials.
   For the moment we may obtain information from in-depth qualitative analysis of documents and interviews with PIs.
- Embedding qualitative data collection in trials is important .....but could we standardise some common coding categories to facilitate meta-analysis/regression.